Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GLS | O94925 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773409 | 1.00 | TDP1 (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1162143 | 0.94 | TDP1 (0.57) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL11682271 | 0.93 | TDP1 (0.60) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL30601919 | 0.93 | TDP1 (0.60) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL5818475 | 0.93 | TDP1 (0.60) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL4580338 | 0.93 | TDP1 (0.60) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL30185439 | 0.88 | GLS (0.57) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1042197 | 0.88 | GLS (0.57) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14605579 | 0.88 | TDP1 (0.44) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7324978 | 0.84 | HEXA (0.67) | MAPTRAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410098-A | Preparation method for synthesizing alpha-aminoketone compound from fatty aldehyde and secondary amine | 西北工业大学 | 2023-07-11 | — | — | CN | claimed |
| US-8916605-B2 | Compounds and methods for treating cancer and viral infections | JUPITER BIOMEDICAL RESEARCH, INC. | 2014-12-23 | — | — | US | claimed |
| CN-102438618-A | Compounds and methods for treating cancer and viral infections | GOFF HILL LTD | 2012-05-02 | — | — | CN | claimed |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | GOFF HILL LIMITED (BB) | 2012-02-09 | — | — | US | claimed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026088120-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| US-12286434-B2 | Pan-tropic entry inhibitors | EMORY UNIVERSITY (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240368146-A1 | Morpholine-Containing & Piperazine-Containing CXCR4 Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240293391-A1 | ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS | UNIV LEUVEN KATH (BE) | 2024-09-05 | — | — | US | disclosed |
| EP-0376819-A1 | Acrylated polyamines, process for their preparation and their use as fungicides | ROUSSEL-UCLAF (FR) | 1990-07-04 | — | — | EP | disclosed |
| US-4650810-A | OR INDOLE-5-THIOACETAMIDES | GLAXO GROUP LIMITED (GB) | 1987-03-17 | — | — | US | disclosed |
| US-4044123-A | ANTIBIOTICS | SCHERING CORPORATION (US) | 1977-08-23 | — | — | US | disclosed |
| US-4002608-A | ANTIBACTERIALS | SCHERING CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
| US-4002742-A | 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor | SCHERING CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
| US-4000261-A | 5-EPI-4,6-DI-O-(AMINOGLYCOSYL)-2-DEOXYSTREPTAMINES, METHODS FOR THEIR MANUFACTURE AND INTERMEDIATES USEFUL THEREIN, METHODS FOR THEIR USE AS ANTIBACTERIAL AGENTS AND COMPOSITIONS USEFUL THEREFOR | SCHERING CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-4000262-A | 5-EPI-AMINO AND 5-EPI-AZIDO-4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXYSTREPTAMINES 1-N-ALKYL-5-EPI-AMINO AND 1-N-ALKYL-5-EPI-AZIDO-4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXYSTREPTAMINES | SCHERING CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-3974209-A | WATER TREATMENT, COMPLEX METAL IONS | MONSANTO COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368146-A1 | Morpholine-Containing & Piperazine-Containing CXCR4 Modulators and Uses Related Thereto | CXCR4, CXCL12, MYD88 | TDP1 4133/4885L3MBTL1 1862/4885MAPT 3900/4885 |
| US-12286434-B2 | Pan-tropic entry inhibitors | CXCR4, CCR5, CXCL12 | TDP1 1633/4885L3MBTL1 3954/4885MAPT 3119/4885 |
| US-20120035238-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS | TP53, RNASE1, FURIN | TDP1 1016/4885L3MBTL1 1644/4885MAPT 1990/4885 |
| US-20260062422-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRD3 | TDP1 2874/4885L3MBTL1 1282/4885MAPT 3710/4885 |
| US-20240293391-A1 | ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS | CXCR4, CCR5, CXCR1 | TDP1 3385/4885L3MBTL1 2831/4885MAPT 2687/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | TDP1 775/4885L3MBTL1 3383/4885MAPT 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.